- 166 Downloads
Raltegravir (Isentress®), an integrase inhibitor, inhibits the insertion of HIV-1 complementary DNA into the host genome. It is indicated in combination with other antiretroviral therapy (ART) agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple ART agents. It is the first of a new class of ART agents to be approved that, as a result of a different mechanism of action to other ART agents, has good activity against multidrug-resistant HIV-1 strains.
In clinical trials in treatment-experienced patients with HIV-1 infection and evidence of viral replication, the addition of oral raltegravir to an optimized background therapy (OBT) regimen improved virological and immunological responses at 16 and 48 weeks to a greater extent than placebo plus OBT. Raltegravir therapy was generally well tolerated, with a similar incidence of mild to moderate adverse events in the treatment and placebo arms. The introduction of integrase inhibitors extends the options available for managing treatment-experienced patients with multiple-drug-resistant HIV-1 infection. Results to date suggest that the combination of raltegravir and OBT will be a valuable treatment option for this difficult-to-treat patient group.
Raltegravir is a selective inhibitor of integrase, an HIV-1-specific enzyme that is responsible for the insertion of viral complimentary DNA into the host genome. In in vitro studies, the 95% inhibitory concentration (IC95) of raltegravir in human T-lymphoid cells infected with a laboratory strain of HIV-1 was 31 nmol/L and ranged from 6 to 50 nmol/L in human peripheral blood mono-nuclear cells, infected with clinical isolates of HIV-1, including strains resistant to other classes of ART. Specific mutations within the HIV-1 integrase gene (predominantly at Q148, N155 or Y143) are correlated with virological resistance to raltegravir. Patients with higher baseline levels of HIV-1 RNA and less active OBT regimens are at the highest risk of integrase mutations arising during treatment.
Oral raltegravir is rapidly absorbed, with a mean maximum plasma concentration reached at a median time of ≈1 hour. The mean plasma concentration of raltegravir at the end of a 12-hour dose administration interval after a 400 mg dose exceeded the IC95 against HIV-1 in vitro. Raltegravir is metabolized in humans through uridine diphosphate-glucuronosyltransferase-mediated glucuronidation in the liver, and is eliminated in faeces and urine. The mean elimination half-life of raltegravir is 7–12 hours. Raltegravir does not significantly affect the activity of the cytochrome P450 system and therefore is not expected to interact with other ART agents that are substrates for these enzymes.
In the two phase III BENCHMRK trials (n = 699), orally administered raltegravir 400 mg twice daily plus OBT improved both virological and immunological outcomes in treatment-experienced patients with HIV-1 infection, evidence of viral replication and HIV-1 strains resistant to multiple ART agents. At 16 weeks in the individual trials and at 48 weeks in the combined analysis, raltegravir plus OBT reduced HIV-1 RNA levels to <400 copies/mL (primary endpoint) and <50 copies/mL in a significantly greater number of patients and significantly increased CD4+ cell counts from baseline when compared with placebo plus OBT. Moreover, prespecified subgroup analyses indicated that in the BENCHMRK trials, the greater efficacy of raltegravir plus OBT compared with placebo plus OBT was maintained in patients with baseline characteristics that typically predict a poor response to ART therapy, for example, higher HIV-1 RNA levels, lower CD4+ cell counts and less active OBT regimens.
Raltegravir was generally well tolerated when used in combination with OBT regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 weeks’ duration. The majority of adverse events were mild to moderate in severity, and of similar incidence in the raltegravir plus OBT and placebo plus OBT treatment arms; treatment-related discontinuations were uncommon. The most common drug-related adverse events reported were diarrhoea, headache, nausea and fatigue.
KeywordsVirological Failure Darunavir Raltegravir Enfuvirtide Integrase Inhibitor
- 1.Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic [online]. Available from URL: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp [Accessed 2008 Nov 26]
- 2.WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008 [online]. Available from URL: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf [Accessed 2008 Nov 26]
- 3.WHO. Global HIV prevalence has levelled off: improvements in surveillance increase understanding of the epidemic, resulting in substantial revisions to estimates [online]. Available from URL: http://www.who.int/mediacentre/news/releases/2007/pr61/en/print.html [Accessed 2008 Nov 26]
- 12.Danovich R, Ke Y, Wan H, et al. Raltegravir has similar in vitro antiviral potency, clinical efficacy, and resistance patterns in B subtype and non-B subtype HIV-1 [abstract no. TUAA0302]. 17th International AIDS Conference; 2008 Aug 3–8; Mexico CityGoogle Scholar
- 18.Isentress (raltegravir): US prescribing information. Whitehouse Station (NJ): Merck and Co., Inc., 2009Google Scholar
- 19.European Medicines Agency. Raltegravir: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/isentress/H-860-PI-en.pdf [Accessed 2009 May 20]
- 24.Hazuda DJ, Miller MD, Nguyen BY. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection [abstract no. 8]. Antiviral Therapy 2007 June 12–16; 12(5): S10Google Scholar
- 28.Wenning LA, Petry A, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1polymorphisms. Clin Pharmacol Ther. Epub 2009 Mar 11Google Scholar
- 29.Wenning L, Anderson M, Petry A, et al. Raltegravir (RAL) dose proportionality and effect of food [abstract no. H-1046]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 35.Iwamoto M, Wenning, LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. Epub 2009 Jan 1Google Scholar
- 36.Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Anti-retroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43(5): 509–15PubMedCrossRefGoogle Scholar
- 38.Wenning L, Hanley W, Brainard D, et al. Effect of rifampin, a potent inducer of drug metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. Epub 2009 May 11Google Scholar
- 39.Hanley W, Wenning L, Moreau A, et al. Effect of tipranavir + ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. Epub 2009 Apr 27Google Scholar
- 42.Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data [abstract no. TUAB0102]. 17th International AIDS Conference; 2008 Aug 3–8; Mexico CityGoogle Scholar
- 43.Steigbigel R, Cooper D, Eron J, et al. 96-week results from BENCHMRK 1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV [abstract no. K-105]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 9–11; Montreal (QC)Google Scholar
- 45.Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial [abstract no. THAB0406]. 17th International AIDS Conference; 2008 Aug 3–8; Mexico CityGoogle Scholar
- 47.De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide (E) to raltegravir (R) in highly treatment-experienced HIV-1 infected patients: a randomized open-label non-inferiority trial (Easier — ANRS 138) [abstract no. 572]. 16th Conference on Retroviuses and Opportunistic Infections; 2009 Feb 8–11; Montreal (QC)Google Scholar
- 48.Cooper D, Steigbigel R, Lennox J, et al. Review of cancer incidence in raltegravir (RAL) clinical trials [abstract no. R-106]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal (QC)Google Scholar
- 49.DHHS panel on antiretroviral guidelines for adults and adolescents: a working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 2008 Nov 26]
- 52.European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe [online]. Available from URL: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf [Accessed 2009 Mar 26]
- 57.Elbasha E, Szucs T, Chaudhary M, et al. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV-1 infected patients in Switzerland [abstract no. TUPDD203]. 17th International AIDS Conference; 2008 Aug 3–8; Mexico CityGoogle Scholar